{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:48:32Z","timestamp":1790704112547,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Study Objectives<\/jats:title><jats:p>To measure the levels of five neurodegenerative biomarkers in the cerebrospinal fluid (CSF) of patients with narcolepsy type 1 (NT1) with variable disease duration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following a standardized protocol of CSF collection and storage, we measured CSF total- and phosphorylated-tau, amyloid-beta 1\u201340 and 1\u201342, and neurofilament light chain (NfL) proteins in 30 nonneurological controls and 36 subjects with NT1, including 14 patients with recent disease onset (i.e. \u226412 months, short disease duration group).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>CSF levels of all biomarkers were similar in NT1 subjects and controls. The comparison between NT1 with short and long disease duration only revealed slightly higher levels of CSF amyloid-beta 1\u201340 in the former group (median 9,549.5, interquartile range [IQR] 7,064.2\u201311,525.0 vs. 6,870.0, IQR 5,133.7\u20139,951.2, p = 0.043). CSF storage time did not influence the levels of the tested biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The measurement of CSF total-tau, phosphorylated-tau, amyloid-beta 1\u201340 and 1\u201342, and NfL proteins is not informative in NT1.<\/jats:p><\/jats:sec>","DOI":"10.1093\/sleep\/zsz215","type":"journal-article","created":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T06:46:04Z","timestamp":1569393964000},"source":"Crossref","is-referenced-by-count":7,"title":["Cerebrospinal fluid biomarkers of neurodegeneration in narcolepsy type 1"],"prefix":"10.1093","author":[{"given":"Simone","family":"Baiardi","sequence":"first","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"},{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pizza","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"},{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Polischi","sequence":"additional","affiliation":[{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Moresco","sequence":"additional","affiliation":[{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Abu-Rumeileh","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Plazzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"},{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9444-9524","authenticated-orcid":false,"given":"Piero","family":"Parchi","sequence":"additional","affiliation":[{"name":"IRCCS, Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy"},{"name":"Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,25]]},"reference":[{"key":"2019101504325362600_CIT0001","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"2","key":"2019101504325362600_CIT0002","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41583-018-0097-x","article-title":"The neurobiological basis of narcolepsy","volume":"20","author":"Mahoney","year":"2019","journal-title":"Nat Rev Neurosci."},{"issue":"7725","key":"2019101504325362600_CIT0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41586-018-0540-1","article-title":"T cells in patients with narcolepsy target self-antigens of hypocretin neurons","volume":"562","author":"Latorre","year":"2018","journal-title":"Nature"},{"issue":"1","key":"2019101504325362600_CIT0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2019101504325362600_CIT0005","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell."},{"issue":"10","key":"2019101504325362600_CIT0006","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"Mignot","year":"2002","journal-title":"Arch Neurol."},{"key":"2019101504325362600_CIT0007","volume-title":"International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2014","edition":"3"},{"issue":"3","key":"2019101504325362600_CIT0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.sleep.2011.10.023","article-title":"Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid","volume":"13","author":"Kallweit","year":"2012","journal-title":"Sleep Med."},{"issue":"6","key":"2019101504325362600_CIT0009","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.sleep.2014.02.005","article-title":"Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy","volume":"15","author":"Heier","year":"2014","journal-title":"Sleep Med."},{"key":"2019101504325362600_CIT0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fnagi.2014.00119","article-title":"Hypocretin and brain \u03b2-amyloid peptide interactions in cognitive disorders and narcolepsy","volume":"6","author":"Dauvilliers","year":"2014","journal-title":"Front Aging Neurosci."},{"issue":"4","key":"2019101504325362600_CIT0011","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jsr.12130","article-title":"CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?","volume":"23","author":"Liguori","year":"2014","journal-title":"J Sleep Res."},{"issue":"1","key":"2019101504325362600_CIT0012","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11325-015-1305-9","article-title":"Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time","volume":"20","author":"Liguori","year":"2016","journal-title":"Sleep Breath."},{"issue":"1","key":"2019101504325362600_CIT0013","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsw006","article-title":"Cerebrospinal fluid biomarkers of neurodegeneration are decreased or normal in narcolepsy","volume":"40","author":"Jennum","year":"2017","journal-title":"Sleep"},{"key":"2019101504325362600_CIT0014","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.dadm.2018.02.005","article-title":"Amyloid \u03b2 peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios","volume":"10","author":"Toombs","year":"2018","journal-title":"Alzheimers Dement (Amst)."},{"issue":"10","key":"2019101504325362600_CIT0015","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jalz.2018.05.008","article-title":"The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: a review","volume":"14","author":"Hansson","year":"2018","journal-title":"Alzheimers Dement."},{"key":"2019101504325362600_CIT0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.sleep.2017.08.021","article-title":"A standardized test to document cataplexy","volume":"53","author":"Vandi","year":"2019","journal-title":"Sleep Med."},{"issue":"1","key":"2019101504325362600_CIT0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","article-title":"The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias","volume":"10","author":"Abu-Rumeileh","year":"2018","journal-title":"Alzheimers Res Ther"},{"issue":"10","key":"2019101504325362600_CIT0018","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00415-008-0983-7","article-title":"Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy","volume":"255","author":"Plazzi","year":"2008","journal-title":"J Neurol."},{"issue":"11","key":"2019101504325362600_CIT0019","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.sleep.2014.07.002","article-title":"May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?","volume":"15","author":"Liguori","year":"2014","journal-title":"Sleep Med."},{"issue":"11","key":"2019101504325362600_CIT0020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.sleep.2014.07.003","article-title":"What happens in the brain in narcolepsy over time?","volume":"15","author":"Heier","year":"2014","journal-title":"Sleep Med."},{"issue":"1\u20132","key":"2019101504325362600_CIT0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(01)02285-6","article-title":"Low cerebrospinal fluid beta-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment","volume":"314","author":"Sj\u00f6gren","year":"2001","journal-title":"Neurosci Lett"},{"issue":"2","key":"2019101504325362600_CIT0022","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s00415-012-6688-y","article-title":"Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections","volume":"260","author":"Krut","year":"2013","journal-title":"J Neurol"},{"issue":"5","key":"2019101504325362600_CIT0023","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1352458512460603","article-title":"Cerebrospinal fluid biomarkers of \u03b2-amyloid metabolism in multiple sclerosis","volume":"19","author":"Augutis","year":"2013","journal-title":"Mult Scler."},{"issue":"8","key":"2019101504325362600_CIT0024","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/sleep\/30.8.980","article-title":"Insufficient non-REM sleep intensity in narcolepsy-cataplexy","volume":"30","author":"Khatami","year":"2007","journal-title":"Sleep."},{"issue":"8","key":"2019101504325362600_CIT0025","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1093\/brain\/awx148","article-title":"Slow wave sleep disruption increases cerebrospinal fluid amyloid-\u03b2 levels","volume":"140","author":"Ju","year":"2017","journal-title":"Brain."},{"issue":"2","key":"2019101504325362600_CIT0026","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1373\/clinchem.2005.058776","article-title":"Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides","volume":"52","author":"Lewczuk","year":"2006","journal-title":"Clin Chem."},{"issue":"4","key":"2019101504325362600_CIT0027","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","article-title":"Amyloid beta peptide ratio 42\/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load","volume":"101","author":"Wiltfang","year":"2007","journal-title":"J Neurochem."},{"issue":"1","key":"2019101504325362600_CIT0028","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/JAD-140771","article-title":"Amyloid-\u03b2 42\/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays","volume":"43","author":"Lewczuk","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"2019101504325362600_CIT0029","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/acn3.274","article-title":"CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"issue":"2","key":"2019101504325362600_CIT0030","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acn3.697","article-title":"Antemortem CSF A\u03b242\/A\u03b240 ratio predicts Alzheimer's disease pathology better than A\u03b242 in rapidly progressive dementias","volume":"6","author":"Baiardi","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"9","key":"2019101504325362600_CIT0031","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1212\/01.wnl.0000256043.50901.e3","article-title":"Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker","volume":"68","author":"Bateman","year":"2007","journal-title":"Neurology."},{"issue":"5955","key":"2019101504325362600_CIT0032","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1126\/science.1180962","article-title":"Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle","volume":"326","author":"Kang","year":"2009","journal-title":"Science."}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsz215\/30145381\/zsz215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsz215\/30145381\/zsz215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T21:01:57Z","timestamp":1695243717000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article\/doi\/10.1093\/sleep\/zsz215\/5573415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,25]]},"references-count":32,"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsz215","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,25]]},"article-number":"zsz215"}}